ATE295163T1 - Verwendung von xanthenon-4-essigsäure zur herstellung eines medikaments für die behandlung von hyperproliferativer störungen - Google Patents

Verwendung von xanthenon-4-essigsäure zur herstellung eines medikaments für die behandlung von hyperproliferativer störungen

Info

Publication number
ATE295163T1
ATE295163T1 AT02004592T AT02004592T ATE295163T1 AT E295163 T1 ATE295163 T1 AT E295163T1 AT 02004592 T AT02004592 T AT 02004592T AT 02004592 T AT02004592 T AT 02004592T AT E295163 T1 ATE295163 T1 AT E295163T1
Authority
AT
Austria
Prior art keywords
xanthenone
mammal
acetic acid
hyperproliferative tissue
photodynamic compound
Prior art date
Application number
AT02004592T
Other languages
English (en)
Inventor
David A Bellnier
Thomas J Dougherty
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Application granted granted Critical
Publication of ATE295163T1 publication Critical patent/ATE295163T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Radiation-Therapy Devices (AREA)
AT02004592T 2001-03-07 2002-02-28 Verwendung von xanthenon-4-essigsäure zur herstellung eines medikaments für die behandlung von hyperproliferativer störungen ATE295163T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/801,163 US6495585B2 (en) 2001-03-07 2001-03-07 Method for treating hyperproliferative tissue in a mammal

Publications (1)

Publication Number Publication Date
ATE295163T1 true ATE295163T1 (de) 2005-05-15

Family

ID=25180358

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02004592T ATE295163T1 (de) 2001-03-07 2002-02-28 Verwendung von xanthenon-4-essigsäure zur herstellung eines medikaments für die behandlung von hyperproliferativer störungen

Country Status (5)

Country Link
US (1) US6495585B2 (de)
EP (1) EP1238666B1 (de)
JP (1) JP2002325853A (de)
AT (1) ATE295163T1 (de)
DE (1) DE60204067T2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39094E1 (en) 1988-07-20 2006-05-09 Health Research, Inc. Pyropheophorbides and their use in photodynamic therapy
USRE38994E1 (en) 1988-07-20 2006-02-28 Health Research, Inc. Pyropheophorbides conjugates and their use in photodynamic therapy
WO2000041725A2 (en) * 1999-01-15 2000-07-20 Light Sciences Corporation Therapeutic compositions for metabolic bone disorders or bone metastases
US20030114434A1 (en) * 1999-08-31 2003-06-19 James Chen Extended duration light activated cancer therapy
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
AU2003248747A1 (en) 2002-06-27 2004-01-19 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
AU2007354255A1 (en) * 2006-11-09 2008-12-04 University Of Maryland, Baltimore Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent
US8180444B2 (en) * 2007-06-22 2012-05-15 Biolitec Pharma Marketing Ltd Enhanced PhotoDynamic Therapy with immune system assist
US20110201678A1 (en) * 2008-10-17 2011-08-18 Masse Craig E Xanthenone-4-Acetic Acid Derivatives
CN109289048B (zh) * 2018-08-08 2021-05-25 南京工业大学 一种肿瘤血管阻断协同光治疗试剂及其合成方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US5002962A (en) * 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
GB9308166D0 (en) * 1993-04-20 1993-06-02 Cancer Res Campaign Tech Cancer therapy

Also Published As

Publication number Publication date
US6495585B2 (en) 2002-12-17
EP1238666A3 (de) 2004-01-07
US20020128303A1 (en) 2002-09-12
DE60204067D1 (de) 2005-06-16
JP2002325853A (ja) 2002-11-12
DE60204067T2 (de) 2006-01-26
EP1238666A2 (de) 2002-09-11
EP1238666B1 (de) 2005-05-11

Similar Documents

Publication Publication Date Title
ATE497778T1 (de) Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus
ATE426405T1 (de) Amino-substituierte diarylaa,ducyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen
DE60200774D1 (de) Mikrobizide und algizide Zusammensetzung, mikrobizides und algizides Verfahren für die Behandlung eines Wassersystems und Verfahren, um eine mikrobizide und algizide Zusammensetzung herzustellen
EP2567705A3 (de) Verfahren zur Behandlung kognitiver Dysfunktion durch Modulation des Energiestoffwechsels des Gehirns
BR0012191A (pt) Processo de redução da concentração de aldeìdo(s) eiou cetona(s) em uma corrente aquosa residual, processo de fabricação de um poliéster ou poliol e processo de fabricação de politrimetileno dicarboxilato
ATE295163T1 (de) Verwendung von xanthenon-4-essigsäure zur herstellung eines medikaments für die behandlung von hyperproliferativer störungen
DE69535498D1 (de) Verfahren zur behandlung vaskulärer kopfschmerzen
DE60144123D1 (de) Verfahren zur Behandlung von Arzneimittelinduzierter peripherer Neuropathie und verwandten Krankheitsformen
ATE492279T1 (de) Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
DE602005002461D1 (de) Einen nanofiltrationsschritt umfassendes verfahren zur aufreinigung von albumin, lösung und zusammensetzung zur therapeutischen anwendung, die dieses enthalten
ATE312809T1 (de) Verfahren zur herstellung von gabapentin
DE69916632T2 (de) Verwendung von zimtsäurederivaten zur herstellung eines medikamentes zur vorbeugung oder behandlung von erkrankungen die durch einen hohen blutfettspiegel bedingt sind
DE69534620D1 (de) Verfahren zur behandlung von augenerkrankungen
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE60130030D1 (de) Verfahren zur behandlung von glaukom
ATE508107T1 (de) Verfahren zur herstellung von gabapentin
DE602004003173D1 (de) Verwendung von konjugierter Linolsäure zur Behandlung der Erkältung
EP1270000A3 (de) Benzoesäure-substituierte Benzopyrane zur Behandlung von Atherosklerose
ATE274927T1 (de) Zusammensetzungen enthaltend monoperphthalatsäure zur behandlung von kontaktlinsen
EP1586555A3 (de) Lagerstabile Iminodisuccinatlösungen
DE50007406D1 (de) Verfahren zur reduzierung von schadorganismen in wasserströmen
RU2002112569A (ru) Способ лечения детей с посттравматическим арахноидитом радоновыми ваннами в комплексе с электромагнитным полем низкой частоты от аппарата "ИНФИТО"
EA200400783A1 (ru) Средство для радикального лечения опухолей, воспалительных процессов, грибковых инфекций и других заболеваний тканей, их диагностика и профилактика и метод его применения
ATE418535T1 (de) Verbessertes verfahren zur herstellung von gabapentin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties